Biotech Values

[RockRat]

ETTX:

Having a major readout scheduled shortly after an IPO is weird...

You're right that IS weird, and inaccurate on my part, and the RockRat regrets the error. I think I saw "2018" when what I was reading was actually 2015. So there is no readout for a while. I believe they'll rehash the P2 for the cUTI drug at IDWeek, but I don't think there's an expectation of major updated data. As such, I don't see any catalysts, except executing on start dates.

My somewhat frustrated take on the Achaogenitis part of my post still stands. The future of the antimicrobial space is combos of existing drugs, some off patent, and no new drug will ever gain market traction. That seems to be the prevailing attitude, and it might be right for a few years, for all I know.

Regards, RockRat